» Articles » PMID: 18505771

The Prevalence and Effects of Adult Attention-deficit/hyperactivity Disorder (ADHD) on the Performance of Workers: Results from the WHO World Mental Health Survey Initiative

Overview
Date 2008 May 29
PMID 18505771
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To estimate the prevalence and workplace consequences of adult attention-deficit/hyperactivity disorder (ADHD).

Methods: An ADHD screen was administered to 18-44-year-old respondents in 10 national surveys in the WHO World Mental Health (WMH) Survey Initiative (n = 7075 in paid or self-employment; response rate 45.9-87.7% across countries). Blinded clinical reappraisal interviews were administered in the USA to calibrate the screen. Days out of role were measured using the WHO Disability Assessment Schedule (WHO-DAS). Questions were also asked about ADHD treatment.

Results: An average of 3.5% of workers in the 10 countries were estimated to meet DSM-IV criteria for adult ADHD (inter-quartile range: 1.3-4.9%). ADHD was more common among males than females and less common among professionals than other workers. ADHD was associated with a statistically significant 22.1 annual days of excess lost role performance compared to otherwise similar respondents without ADHD. No difference in the magnitude of this effect was found by occupation, education, age, gender or partner status. This effect was most pronounced in Colombia, Italy, Lebanon and the USA. Although only a small minority of workers with ADHD ever received treatment for this condition, higher proportions were treated for comorbid mental/substance disorders.

Conclusions: ADHD is a relatively common condition among working people in the countries studied and is associated with high work impairment in these countries. This impairment, in conjunction with the low treatment rate and the availability of cost-effective therapies, suggests that ADHD would be a good candidate for targeted workplace screening and treatment programs.

Citing Articles

Validity of the Italian Version of DIVA-5: Semi-Structured Diagnostic Interview for Adult ADHD Based on the DSM-5 Criteria.

Di Lorenzo R, Latella E, Gualtieri F, Adriani A, Ferri P, Filippini T Healthcare (Basel). 2025; 13(3).

PMID: 39942433 PMC: 11816683. DOI: 10.3390/healthcare13030244.


Digital assessments for children and adolescents with ADHD: a scoping review.

Cibrian F, Monteiro E, Lakes K Front Digit Health. 2024; 6:1440701.

PMID: 39439849 PMC: 11493775. DOI: 10.3389/fdgth.2024.1440701.


ADHD: prevalence and effect on opioid use disorder treatment outcome in a French sample of patients receiving medication for opioid use disorder-the influence of impulsivity as a mediating factor.

Beslot A, Grall-Bronnec M, Balem M, Schreck B, Laforgue E, Victorri-Vigneau C Harm Reduct J. 2024; 21(1):165.

PMID: 39252018 PMC: 11382469. DOI: 10.1186/s12954-024-01079-7.


From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care.

Baweja R, Faraone S, Childress A, Weiss M, Loo S, Wilens T J Child Adolesc Psychopharmacol. 2024; 34(4):167-182.

PMID: 38686563 PMC: 11302246. DOI: 10.1089/cap.2024.0022.


Sluggish Cognitive Tempo as a Transdiagnostic Link Between Adult ADHD and Internalizing Symptoms.

Kamradt J, Eadeh H, Nikolas M J Psychopathol Behav Assess. 2024; 44(3):699-712.

PMID: 38221987 PMC: 10786088. DOI: 10.1007/s10862-021-09926-8.


References
1.
Ratey J, Greenberg M, Bemporad J, Lindem K . Unrecognized attention-deficit hyperactivity disorder in adults presenting for outpatient psychotherapy. J Child Adolesc Psychopharmacol. 2009; 2(4):267-75. DOI: 10.1089/cap.1992.2.267. View

2.
Swensen A, Birnbaum H, Secnik K, Marynchenko M, Greenberg P, Claxton A . Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry. 2003; 42(12):1415-23. DOI: 10.1097/00004583-200312000-00008. View

3.
Spencer T, Biederman J, Wilens T, Faraone S, Prince J, Gerard K . Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001; 58(8):775-82. DOI: 10.1001/archpsyc.58.8.775. View

4.
Simpson D, Plosker G . Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs. 2004; 18(6):397-401. DOI: 10.2165/00023210-200418060-00011. View

5.
Kessler R, Adler L, Ames M, Demler O, Faraone S, Hiripi E . The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005; 35(2):245-56. DOI: 10.1017/s0033291704002892. View